Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Battle of the scopes: which technique best wipes out Barrett's lesions?

NCT ID NCT05276791

Disease control Sponsor: St. Antonius Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial compares two endoscopic procedures—endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD)—for removing visible precancerous lesions in people with Barrett's esophagus. About 331 adults with Barrett's esophagus and early-stage abnormal tissue will be randomly assigned to one of the two techniques. The goal is to see which method more completely removes the lesions and prevents them from coming back within a year, without using ablation therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)
What this could lead to
If one technique proves superior, it could become the standard approach for removing early-stage lesions in Barrett's esophagus, reducing the risk of cancer progression.
What could go wrong
This is a single trial with 331 participants, and results may not apply to all patients. ESD is more complex and carries a higher risk of complications like bleeding or perforation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 331 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients age: ≥ 18 years * Willingness to undergo both EMR or ESD * Ability to provide written, informed consent (approved by IRB) and understand the responsibilities of trial participation * BE with at least one visible lesion ("target lesion") with absence of signs of submucosal invasion on endoscopy, after evaluation by the adjudication committee * Multiple lesions are allowed as long as the lesions are considered eligible for endoscopic treatment. Only the target lesion is evaluated for the study * Prior endoscopic resection is allowed Exclusion Criteria: * Patients with visible lesions with suspicion of submucosal invasion based on assessment of the adjudication committee * Patients with HGD in at least one random biopsy, before inclusion (i.e. during endoscopy in the referring center \<3 months before imaging, or during imaging endoscopy) * History of esophageal surgery other than fundoplication * History of esophageal ablation therapy * In case of prior endoscopic resection, the target lesion located within 1 cm of the prior resection site * Uncontrolled coagulopathy with INR \>2.0, thrombocytopenia with platelet counts \< 50,000 * Esophageal varix or varices * Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines * Life expectancy \<2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Barrett adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Barrett adenocarcinoma Barrett esophagus esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Barrett adenocarcinoma Barretts esophagus with dysplasia Esophageal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam University Medical Center

    RECRUITING

    Amsterdam, Netherlands

  • Catharina Ziekenhuis

    RECRUITING

    Eindhoven, Netherlands

  • Erasmus Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • St. Antonius Ziekenhuis

    RECRUITING

    Nieuwegein, Netherlands

  • University Medical Center Groningen

    RECRUITING

    Groningen, Netherlands

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.